论文部分内容阅读
1982年12月23日,在上海市卫生局及上海市医药局主持下,对治疗肝昏迷新药14氨基酸注射液-800(简称14AA-800)举行了鉴定会。到会的有医药专家及有关代表共100余人。会上先由上海医工院、上海第二医学院附属瑞金医院及长征制药厂分别介绍了14AA-800的制剂工艺、作用机制、临床效果及制剂规格。随后与会代表进行了认真的讨论与鉴定,最后一致通过鉴定。14AA-800是根据当前肝昏迷发病机制中血清氨基酸平衡失调学说而设计的。在测定正常人和各种肝病及肝昏迷患者的血清氨基酸,尤其是支链氨基酸与芳香氨基酸的比值(简称支/芳比值)的研究中,人们发现在严重肝病和肝昏迷时,支/芳比值明显低于正常。因此有
December 23, 1982, under the auspices of the Shanghai Municipal Bureau of Health and the Shanghai Medical Board, the treatment of liver coma new drug 14 amino acid injection -800 (referred to as 14AA-800) held an appraisal meeting. There will be a total of more than 100 medical experts and related representatives. The 14AA-800 preparation process, mechanism of action, clinical effect and formulation specifications were introduced respectively by Shanghai Medical Institute, Ruijin Hospital affiliated to Shanghai Second Medical College and Changzheng Pharmaceutical Factory. Subsequent representatives and representatives conducted a serious discussion and identification, and finally unanimously approved. 14AA-800 is based on the current theory of disorders of serum amino acid balance in the pathogenesis of hepatic coma. In the determination of normal subjects and a variety of liver disease and hepatic coma in patients with serum amino acids, especially branched-chain amino acids and aromatic amino acid ratio (referred to as branch / aromatic ratio) of the study, it was found in severe liver disease and hepatic coma, branch / Fang Ratio was significantly lower than normal. So there